Skip to main content

Table 3 Domain ratings between patient subgroups

From: Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials

 

Male

Female

Age < 55 years

Age ≥ 55 years

OA

RA

THR

TKR

Core domains

 Joint pain

8 (7–9)

9 (8–9)

9 (7–9)

9 (8–9)

9 (8–9)

9 (7–9)

9 (8–9)

9 (7–9)

***

  

**

 Function

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

***

*

*

 

 Patient satisfaction

8 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

9 (8–9)

8 (8–9)

9 (8–9)

8 (8–9)

***

  

***

 Revision surgery

7 (4–9)

8 (5–9)

7 (5–9)

8 (5–9)

8 (5–9)

7 (5–9)

8 (5–9)

7 (5–9)

***

   

 Adverse events

8 (6–9)

9 (7–9)

8 (7–9)

8 (7–9)

8 (7–9)

8 (5–9)

8 (7–9)

8 (6–9)

***

   

 Death

9 (5–9)

9 (6–9)

9 (6–9)

9 (6–9)

9 (6–9)

8 (6–9)

9 (7–9)

9 (5–9)

***

  

*

Additional domains

        

 Cost

7 (5–8)

7 (5–9)

7 (5–8)

7 (5–8)

7 (5–8)

7 (5–9)

7 (5–8)

7 (5–8)

***

*

  

 Patient participation

7 (6–9)

8 (7–9)

8 (6–9)

8 (6–9)

8 (6–9)

8 (7–9)

8 (6–9)

8 (6–9)

***

   
  1. Abbreviations: OA Osteoarthritis, RA Rheumatoid arthritis, THR Total hip replacement, TKR Total knee replacement
  2. Significant p values are denoted as follows: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Blank values underneath each pair of median (IQR) indicate no statistical significance. Each domain was rated on a 1–9 scale, with 1–3 indicating limited or no importance for patients, 4–6 being important but not critical, and 7–9 being critical